U.S. Equity Strategy: Round Trip Back To Resistance
Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the...
216 Views
Adaptive Biotechnologies IPO: Immune to Grow and Succeed; and the Future Looks Good
Adaptive Biotechnologies (ADPT US) has filed for an IPO in the US to raise approximately US$181m and has set an IPO price range of US$15-17 per...
352 Views
Personalis IPO: Personalising Cancer Trials and Treatments; Upside from Growth in Cancer Market
Personalis offers genomic sequencing to bio-pharmaceutical companies by fully analyzing sample tissue data of cancer patients. It provides its...
581 Views
No more insights